This trial is the first phase II study to report single-agent activity of abemaciclib, a selective inhibitor of CDK4 and CDK6, in patients with HR + /HER2 − MBC who have progressed on or after prior ...

Here, we introduce BBO-8520, a potent, selective, orally bioavailable, direct covalent inhibitor of KRAS G12C, with dual activity against both the (OFF) and (ON) states of KRAS G12C. BBO-8520 is ...

Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

Our study addresses the urgent need for treatment strategies for TKI-resistant gastrointestinal stromal tumors (GIST). We have identified a non-TKI compound, OPB-171775, that exhibits significant ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

Abstract. Introduction: Antibody and peptide-conjugated drugs are rapidly entering the clinic for the treatment of patients with early and advanced breast cancer. These drugs are designed to achieve ...

Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...

Immunotherapy has been an unsuccessful strategy in the treatment of hormone receptor–positive, HER2-negative breast cancer. Pelareorep (Pel), an oncolytic reovirus, improved overall survival when ...

RAS inhibition has the potential to transform cancer treatment for many patients. The landscape of RAS inhibitor therapies is rapidly evolving, with two mutant-selective KRAS inhibitors now approved ...

AbstractPurpose:. Patients with melanoma progressing on immune checkpoint blockade may benefit from adoptive transfer of tumor-infiltrating lymphocytes (TIL).Patients and Methods:. We investigated the ...

Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been ...

The most common treatment-related grade 1–2 adverse events were vascular disorders including transient hypotension (18 patients, 46%), flushing (11 patients, 28%), and injection site reactions in 38% ...